# LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

> **NCT03725605** · PHASE2 · COMPLETED · sponsor: **Lytix Biopharma AS** · enrollment: 6 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **COMBINATION_PRODUCT:** LTX-315 and TILs

## Key facts

- **NCT ID:** NCT03725605
- **Lead sponsor:** Lytix Biopharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-28
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-10-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03725605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03725605, "LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03725605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*